Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

COPD Progression Slowed With Umeclidinium/Vilanterol vs. Fluticasone Propionate/Salmeterol

Key clinical point: Patients with chronic obstructive pulmonary disease (COPD) fared better on an inhaled fixed-dose long-acting muscarinic antagonist/long-acting β2-agonist vs. an inhaled corticosteroid.

Major finding: Patients who began umeclidinium/vilanterol (62.5/25 msg) therapy were less likely to progress to multiple-inhaler triple therapy (hazard ratio = 0.65; 95% CI, 0.47–0.89; P = .008) vs. fluticasone propionate/salmeterol (250/50 msg).

Study details: Retrospective observational analysis in COPD of 386 patients who began UMEC/VI and 3,920 who began FP/SAL.

Disclosures: GlaxoSmithKline, maker of Anoro Ellipta (umeclidinium/vilanterol), funded the study. The authors report various disclosures, and some are GlaxoSmithKline employees and stockholders.